髋关节发育不良治疗中骨化核存在与骨坏死风险的关联:队列与病例对照研究的Meta分析
该Meta分析系统检索MEDLINE、Embase和Cochrane数据库,纳入21项观察性研究(18项回顾性、3项前瞻性),评估髋关节发育不良(DDH)复位时骨化核存在与否与骨坏死风险的关联。结果显示骨化核存在组骨坏死发生率为20.4%,缺失组为21.2%;骨化核存在与任何级别骨坏死(OR=0.70,95%CI=0.43-1.12)及II-IV级严重骨坏死(OR=0.70,95%CI=0.30-1.17)的降低均无统计学显著关联。Meta回归未发现复位平均年龄、复位方法、手术入路、研究质量、随访时长、骨化核影像评估方法或骨坏死分类系统对该关系有影响。
要点
- 骨化核存在组骨坏死发生率20.4%,缺失组21.2%,两组差异无统计学显著。
- 骨化核存在与任何级别骨坏死风险降低无显著关联(OR=0.70,95%CI=0.43-1.12)。
- 骨化核存在与II-IV级严重骨坏死风险降低无显著关联(OR=0.70,95%CI=0.30-1.17)。
核心结论
- 当前文献不支持复位时骨化核存在与骨坏死风险降低相关的假设。
- 需要前瞻性研究、长期随访和盲法评估者来最佳评估潜在危险因素与骨坏死发生的关系。
研究设计与样本
- 系统检索MEDLINE、Embase和Cochrane数据库,纳入评估DDH开放或闭合复位后骨化核状态与骨坏死发生率的研究。
- 共纳入21项观察性研究,其中18项回顾性研究、3项前瞻性研究。
- 采用Newcastle-Ottawa量表评估研究质量,采用随机效应模型计算合并效应量,并用Meta回归评估复位方法、研究质量、复位平均年龄、手术入路、骨化核评估方法和随访时长与骨坏死 odds 的关系。
主要发现
- 骨化核存在组骨坏死发生率为20.4%,骨化核缺失组为21.2%。
- 骨化核存在与任何级别骨坏死风险降低无显著关联(OR=0.70,95%CI=0.43-1.12)。
- 骨化核存在与II-IV级严重骨坏死风险降低无显著关联(OR=0.70,95%CI=0.30-1.17)。
- Meta回归未显示复位平均年龄、复位方法、手术入路、研究质量、最短或平均随访时长、骨化核影像评估方法或骨坏死分类系统对骨化核存在与骨坏死风险关系有任何影响。
关键数值与推荐
- 骨化核存在组骨坏死发生率20.4%,骨化核缺失组21.2%。
- 任何级别骨坏死:OR=0.70,95%CI=0.43-1.12。
- II-IV级骨坏死:OR=0.70,95%CI=0.30-1.17。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要前瞻性研究、长期随访和盲法评估者来最佳评估潜在危险因素与骨坏死发生的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concern for increased risk of osteonecrosis in hips with an absent ossific nucleus has led some surgeons to delay reduction in the treatment of developmental dysplasia of the hip (DDH) until the ossific nucleus is present. A previous meta-analysis reported a potential protective effect against high-grade osteonecrosis (II to IV) when the ossific nucleus was present. With a greater number of publications on this topic, revisiting this analysis is warranted. The aim of this meta-analysis was to systematically review and analyze the best clinical evidence regarding the association between the status of the ossific nucleus and development of osteonecrosis following the treatment of DDH. METHODS: MEDLINE, Embase, and Cochrane databases were systematically searched for studies including the status of the ossific nucleus and rate of osteonecrosis after open and closed reductions for the treatment of DDH. Study characteristics and risk estimates were extracted. Study quality was assessed using the Newcastle-Ottawa Scale. Pooled effect estimates were calculated using a random-effect model. Meta-regression assessed the relationships of reduction method, study quality, mean age at reduction, surgical approach, method of ossific nucleus assessment, and duration of follow-up to the odds of osteonecrosis. RESULTS: In the 21 observational studies (18 retrospective, 3 prospective) that were included, osteonecrosis developed in 20.4% of the hips in which the ossific nucleus was present at reduction compared with 21.2% of the hips in which the ossific nucleus was absent. Presence of the ossific nucleus was not associated with decreased odds of any grade of osteonecrosis (odds ratio [OR] = 0.70, 95% confidence interval [CI] = 0.43 to 1.12) or of more severe osteonecrosis of Grades II to IV (OR = 0.70, 95% CI = 0.30 to 1.17). Meta-regression did not show any effect of the mean age at reduction, reduction method, surgical approach, study quality, minimum or mean duration of follow-up, method of ossific nucleus imaging, or osteonecrosis classification system on the relationship between presence of the ossific nucleus and the risk of osteonecrosis. CONCLUSIONS: The current literature does not support the hypothesis that presence of the ossific nucleus at reduction is associated with lower risk of osteonecrosis. Prospective studies with long-term follow-up and blinded assessors are warranted to optimally evaluate the relationship between potential risk factors and the development of osteonecrosis. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
引用
- Chen C, Doyle S, Green D, et al. Presence of the Ossific Nucleus and Risk of Osteonecrosis in the Treatment of Developmental Dysplasia of the Hip: A Meta-Analysis of Cohort and Case-Control Studies. J Bone Joint Surg Am. 2017. PMID: 28463920. doi:10.2106/JBJS.16.00798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。